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Personalized medicine is typically described as the use of molecular or genetic characteristics to
customize therapy. This perspective at best provides an incomplete model of the patient and at
worst can lead to grossly inappropriate practices. Personalization of medicine requires two charac-
terizations: a well-grounded understanding of who the patient is and an equally robust under-
standing of the subpopulation that most resembles that patient in the context of the decisions at
hand. These characterizations are readily represented probabilistically and can be used to drive
decision-making in a rational manner that maximizes the positive outcomes for the patient.
Wikipedia [1] defines personalized medicine as the “use of
information and data from a patient’s genotype, or level of
gene expression to stratify disease, select a medication,
provide a therapy, or initiate a preventative measure that is
particularly suited to that patient at the time of adminis-
tration.” Other data types are then mentioned as being
equally important. A more conventionally authoritative
source [2] defines personalized medicine as “The use of
genetic susceptibility or pharmacogenetic testing to tailor an
individual’s preventive care or drug therapy.” This apparent
primacy of molecular or genetic measurements obscures the
fact that they are both only one of many clinical charac-
terizations, and often not the most important one.
An alternative definition, arising from more than 50 years of
clinical decision science [3], holds that personalized
medicine is the practice of clinical decision-making such that
the decisions made maximize the outcomes that the patient
most cares about and minimizes those that the patient fears
the most, on the basis of as much knowledge about the
individual’s state as is available. To be able to contemplate
such a personalized medicine practice, two fundamental
questions have to be answered. First, what are the relevant
patient characteristics? Second, which clinically distinct
subgroup of patients does this patient most resemble?
The second question defines the knowledge that we have
about how a group of clinically relevant patients are likely to
respond to a given intervention or what the accuracy and
specificity of a particular test are when applied to that
subgroup. The first question is important because the deeper
our understanding of who the patient is, the more accurately
we can identify which subgroup or subgroups (s)he might
belong to, and the more accurately we can assess the level of
confidence that the match to that group is relevant. Stated
differently, information about the patient is of very limited
utility without the knowledge derived from experience or
measurements of a group of similar patients and evidence as
to which is the best comparison group. The mapping of that
knowledge from one or more circumscribed groups to the
patient’s information is what defines the personalization of
medicine. Therefore, I argue here that answering these two
questions is central to a safe, effective, and sustainable
delivery of personalized medicine.
So, who are you? What are your personal characteristics so
that we can define personalized medicine? What about your
race? Is that a relevant characteristic? And if so, how do we
measure it [4]? Should we ask an individual what their racial
background is? Or should we simply perform a genome-wide
scan and use common polymorphisms to identify, with very
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on the basis of as little as 50 random single nucleotide poly-
morphisms [5]? Is this genomic characterization sufficient
and does it obviate the need to ask the individual what is
their race or continent of origin?
On brief reflection it becomes obvious that the genome is not
sufficient. An African American of Yoruban origin might be
genomically very similar to a number of Yorubans living in
Nigeria, but as a result of different exposures, cultural
practices, and availability of medical services, the indi-
vidual’s self identification may be just as important as their
shared genetic background with individuals in Africa.
Whereas individual genotypes can be known with a high
certainty [6], other characteristics such as knowledge of
one’s average blood pressure, caloric intake or family history
are known with much less accuracy and with varying degrees
of certainty. Nonetheless, all the characterizations of an
individual, ranging from the genomic to the behavioral, are
observations that each have a probabilistically expressible
degree of certainty [7,8].
Now what about group membership: whom do you most
resemble? Most medical knowledge about treatment
response and diagnostic categories and physiologies rests on
observations made on groups of patients. Take, for example,
the effect of glycemic control on retinopathy of type 1
diabetes patients as a function of their glycohemoglobin [9];
the time to recurrence of HER2-positive breast cancer
patients [10]; or the degree of shared allergenicity of various
insulin-derived antibiotics [11]: all these pieces of knowledge
are based on characterization of subgroups of patients
defined as having some shared characteristics that define
their group within a formal study or by anecdote. Here,
again, the characteristics of the group can range from
genetic to behavioral characterizations, and for each
subgroup of patients there is a set of medical character-
izations, whether they be therapeutic susceptibility or
prognostic course, that are known with varying degrees of
certainty. Therefore, these assertions can be expressed
probabilistically too.
Without a well grounded estimate of who you are, and
therefore which group you are most likely to resemble, some
significant misassignment and erroneous personalization
can occur, even despite the availability of genetic infor-
mation, or sometimes, as in the following well documented
case, because of it.
Hemochromatosis is an iron-storage disease with multi-
system effects that eventually lead to premature death, and it
is known to have a genetic basis. A homozygous G845>A
mutation in the HFE gene is found in 80% of patients with
inherited hemochromatosis in genetic clinics [12,13] and has
been thought of as a classically Mendelian inherited, highly
penetrant mutation. However, a group of investigators
screening over 40,000 patients in an outpatient setting found
that, of the 152 patients that were homozygous for the G845>A
mutation in HFE, only one of them had any historical, physical,
or biochemical evidence of hemochromatosis [14]. These
results suggest that this mutation, rather than being highly
penetrant, is in fact a relatively common mutation whose
penetrance is not 100% but closer to 1%.
How could so many genetics clinics be wrong about the value
of this test? In the two instances, the patient subgroups
being identified and the patients being identified were very
different populations. In a genetics clinic, the patients
usually evaluated are already under a high suspicion for
having hemochromatosis, either because of family history,
or because of biochemical or clinical evidence of iron over-
load. These characteristics are essential parts of the ‘who are
you?’ question of personalized medicine. A personalized
medicine would and must distinguish patients who may be
homozygous for the same mutation of the HFE gene but who
otherwise differ in other important characteristics; they
therefore should be given very different risk profiles because
of the consequent different answers to the question ‘who do
you most resemble?’ Some hints as to what these other
characteristics may be, in this instance of inherited
hemochromatosis, are pointed to by several reports. These
include a French study [15] that showed that the penetrance
of the HFE mutation is a function of alcohol consumption.
Other studies suggest sex-dependent modifier genes [16]
that also change the patient’s physiology and therefore affect
their correspondence to subgroups with different risk profiles.
What, then, does this imply for a safe and effective practice
of genomic medicine? How can we avoid an avalanche of
alarming false positive diagnostics and prognostics (that is,
the ‘incidentalome’ [17])? Given that more and more genetic
testing will occur in the outpatient setting or even in the
direct-to-consumer setting, the preceding discussion
suggests that what is called for is increased precision and
quantification of the individuals’ complete health state, and
increased precision and breadth with which populations are
characterized. Institutional electronic medical records provide
some promise for characterization of a patient’s complete
health state, as do personal health records, depending on
how these evolve in the future [18]. The efficient charac-
terization of populations will require systematization of
epidemiology augmented by genomics, involving the
harmonization of data standards, new analytical methods
and marshalling of populations to a level that dwarfs all
previous epidemiological efforts [19]. The representation of
all these data in the aforementioned probabilistic framework
will enable the application of time-tested and rigorous
methods for personalized decision-making in a readily
computable manner [20-22] to maximize the utility of health
outcomes. Whose utilities are being maximized, society’s or
the patient’s, is a crucial policy discussion in the develop-
ment of funding models for personalized medicine [23].
http://genomemedicine.com/content/1/1/4 Genome Medicine 2009, Volume 1, Issue 1, Article 4 Kohane 4.2
Genome Medicine 2009, 1 1: :4In summary, the key to successful fulfillment of the expec-
tations for the personalized medicine era will not be driven
primarily by finding new molecular targets with which to
direct customized therapy. As illustrated above, a too narrow
focus on genetic variation fundamentally blinds us to the
personalized information that can and should guide our
clinical decision-making for individuals. Personalized infor-
mation should extend to observables such as the environ-
ment and physiology, which cannot be easily inferred from
examining genome-scale variation. We have to revisit what
the  best clinicians have always done: gather together as
comprehensive a perspective on the individual patient’s
condition as possible, and see the extent to which that
patient’s perspective fits into the sets of similar patients that
were previously encountered. Fortunately, unlike the expert
physicians of previous eras, we now have the automated
means with which to do this on an industrial scale. However,
to use this automation effectively will require the incorpora-
tion of computer-assisted decision-making throughout
medical practice and the education of our clinicians in the
effective use of such assistive devices. These goals are likely to
stand as two of the most challenging of personalized medicine.
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